S-Adenosylhomocysteine: a better indicator of vascular disease than homocysteine?
- PMID: 18065573
- DOI: 10.1093/ajcn/86.5.1581
S-Adenosylhomocysteine: a better indicator of vascular disease than homocysteine?
Abstract
It is widely accepted that elevated plasma total homocysteine is an independent risk factor for vascular disease. The relation is believed to be causal, but there is no generally accepted mechanism for the pathophysiology involved. The metabolic precursor of homocysteine in all tissues is S-adenosylhomocysteine (AdoHcy). AdoHcy is present in normal human plasma at concentrations approximately 1-500th of those of homocysteine, a fact that presents difficulties in measurement. The requirement for specialized equipment, complicated time-consuming methodology, or both is a reason that measurement of plasma AdoHcy has not generally been carried out in large studies. A recently published rapid immunoassay for AdoHcy in human plasma should make measurement of this important metabolite available for general use. Advantages of the measurement of plasma AdoHcy include 1) a smaller overlap of values between control subjects and patients, and thus the possibility of observing significant differences in fewer samples, 2) an accepted mechanism of metabolic activity as an inhibitor of all S-adenosylmethionine-mediated methyltransferases, and 3) evidence (from recent studies) that a higher plasma concentration of AdoHcy is a more sensitive indicator of vascular disease than is a higher plasma concentration of homocysteine.
Similar articles
-
Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations.Br J Nutr. 2010 Jun;103(11):1629-34. doi: 10.1017/S0007114509993552. Epub 2010 Jan 21. Br J Nutr. 2010. PMID: 20089204 Clinical Trial.
-
Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease.Clin Chem. 2003 Aug;49(8):1292-6. doi: 10.1373/49.8.1292. Clin Chem. 2003. PMID: 12881445
-
Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine.Am J Clin Nutr. 2001 Dec;74(6):723-9. doi: 10.1093/ajcn/74.6.723. Am J Clin Nutr. 2001. PMID: 11722952
-
Role of S-adenosylhomocysteine in cardiovascular disease and its potential epigenetic mechanism.Int J Biochem Cell Biol. 2015 Oct;67:158-66. doi: 10.1016/j.biocel.2015.06.015. Epub 2015 Jun 24. Int J Biochem Cell Biol. 2015. PMID: 26117455 Review.
-
Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine.Clin Chem Lab Med. 2007;45(12):1694-9. doi: 10.1515/CCLM.2007.341. Clin Chem Lab Med. 2007. PMID: 17963455 Review.
Cited by
-
Development and validation of an LC-MS/MS assay for the quantification of the trans-methylation pathway intermediates S-adenosylmethionine and S-adenosylhomocysteine in human plasma.Clin Chim Acta. 2013 Jun 5;421:91-7. doi: 10.1016/j.cca.2013.03.003. Epub 2013 Mar 13. Clin Chim Acta. 2013. PMID: 23499573 Free PMC article.
-
Comment on: Song et al. (2009) Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 58:1921-1928.Diabetes. 2010 Mar;59(3):e1. doi: 10.2337/db09-1543. Diabetes. 2010. PMID: 20190132 Free PMC article. No abstract available.
-
Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40-65: a prospective cross-sectional study.Cardiovasc Diabetol. 2023 Aug 24;22(1):219. doi: 10.1186/s12933-023-01942-0. Cardiovasc Diabetol. 2023. PMID: 37620823 Free PMC article.
-
Effects of methionine synthase and methylenetetrahydrofolate reductase gene polymorphisms on markers of one-carbon metabolism.Genes Nutr. 2013 Nov;8(6):571-80. doi: 10.1007/s12263-013-0358-2. Epub 2013 Oct 8. Genes Nutr. 2013. PMID: 24101362 Free PMC article.
-
Metabolomics Deciphering the Potential Biomarkers of Hengqing I Prescription against Vascular Dementia.Evid Based Complement Alternat Med. 2022 Mar 30;2022:1636145. doi: 10.1155/2022/1636145. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35399642 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical